NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Septerna discontinues phase 1 clinical trial of SEP-786; plans to advance next-generation oral small molecule PTH1R agonist: South San Francisco, California Friday, February 21, 2 ...

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Septerna (NASDAQ:SEPN – Get Free Report) was downgraded by equities researchers at Wells Fargo & Company from an “overweight” rating to an “equal weight” rating in a research note issued on Tuesday, ...

MRNA and GILD are in the spotlight this week on fourth-quarter earnings release and regulatory update, respectively.

MRNA and GILD are in the spotlight this week on fourth-quarter earnings release and regulatory update, respectively.

Fintel reports that on February 18, 2025, Wells Fargo downgraded their outlook for Septerna (NasdaqGM:SEPN) from Overweight ...

US clinical-stage biotech Septerna yesterday announced its decision to discontinue the Phase I single- and multiple-ascending ...

Septerna Inc. has announced its decision to discontinue a healthy volunteer phase I trial of SEP-786, an oral small-molecule agonist of the parathyroid hormone 1 receptor being developed for the ...

Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 gaining 0.25%, China's Shanghai Composite Index falling 0.93%, Hong Kong's Hang Seng Index gaining 1.59% and India's BSE Sensex falling 0 ...

Septerna halts Phase 1 trial of SEP-786 for hypoparathyroidism due to safety concerns, FDA approves Sanofi's Merilog insulin biosimilar, plus updates from Basilea and TME Pharma ...